2023
Cognitive impairment in pulmonary arterial hypertension
Heller S, See C, Singh I, Fredericks C. Cognitive impairment in pulmonary arterial hypertension. Annals Of Clinical And Translational Neurology 2023, 10: 1899-1903. PMID: 37550957, PMCID: PMC10578884, DOI: 10.1002/acn3.51867.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionCognitive impairmentArterial hypertensionPulmonary artery pressureRight heart dysfunctionPulmonary vascular remodelingCognitive impairment syndromeVascular cognitive impairmentArtery pressureCardiopulmonary exerciseHeart dysfunctionNoninvasive markerCognitive dysfunctionVascular remodelingAdult subjectsImpairmentHypertensionUnderlying mechanismAbnormal increaseDysfunctionSyndromeCognitive evaluationSubjectsResponse to letter to the editor “noninvasive determinants of pulmonary hypertension in interstitial lung disease”
Joseph P, Savarimuthu S, Oakland H, Cullinan M, Heerdt P, Singh I. Response to letter to the editor “noninvasive determinants of pulmonary hypertension in interstitial lung disease”. Pulmonary Circulation 2023, 13: e12238. PMID: 37180828, PMCID: PMC10166920, DOI: 10.1002/pul2.12238.Peer-Reviewed Original Research
2021
Chronic Thromboembolic Pulmonary Hypertension: the Bench
Alba GA, Atri D, Darbha S, Singh I, Tapson VF, Lewis MI, Chun HJ, Yu YR, Maron BA, Rajagopal S. Chronic Thromboembolic Pulmonary Hypertension: the Bench. Current Cardiology Reports 2021, 23: 141. PMID: 34410515, DOI: 10.1007/s11886-021-01572-6.Peer-Reviewed Original ResearchConceptsPulmonary embolismAcute pulmonary embolismThromboembolic pulmonary hypertensionPlatelet-rich thrombiPulmonary hypertensionUncommon complicationMedical therapyPulmonary vasculatureImmune cellsAnimal modelsEndothelial cellsPathobiologyPlatelet biologyThrombusHuman samplesTherapyCurrent knowledgeSummaryThe developmentCTEPHHypertensionVasculopathyCellsComplicationsEmbolismInflammationChronic Thromboembolic Pulmonary Hypertension: the Bedside
Matusov Y, Singh I, Yu YR, Chun HJ, Maron BA, Tapson VF, Lewis MI, Rajagopal S. Chronic Thromboembolic Pulmonary Hypertension: the Bedside. Current Cardiology Reports 2021, 23: 147. PMID: 34410530, PMCID: PMC8375459, DOI: 10.1007/s11886-021-01573-5.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionPulmonary embolismMedical therapyRight ventricular failureThromboembolic pulmonary hypertensionAcute pulmonary embolismArterial hypertensionPulmonary hypertensionVentricular failureUncommon complicationDisease mimicsPulmonary vasculatureMultimodality approachUnderlying pathologyPercutaneous interventionCurrent diagnosisCTEPHHypertensionTherapyDiagnosisTreatmentEmbolismComplicationsEmboliSurgeryQuantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging
Rahaghi FN, Nardelli P, Harder E, Singh I, Sánchez-Ferrero GV, Ross JC, San José Estépar R, Ash SY, Hunsaker AR, Maron BA, Leopold JA, Waxman AB, San José Estépar R, Washko GR. Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging. CHEST Journal 2021, 160: 2220-2231. PMID: 34270966, PMCID: PMC8692106, DOI: 10.1016/j.chest.2021.06.069.Peer-Reviewed Original ResearchConceptsExercise pulmonary hypertensionPulmonary arterial hypertensionControl subjectsPulmonary hypertensionSmall vessel volumeArterial hypertensionPulmonary arteryPulmonary vasculatureVascular tortuosityVascular volumeArterial volumePrecapillary pulmonary hypertensionCohort of patientsPulmonary vascular volumeVenous manifestationsThromboembolic diseaseCT angiogramArterial tortuosityHypertensionCT scanVessel volumeHeterogeneous diseasePatientsStudy designArteryPressure-based estimation of right ventricular ejection fraction: Validation as a clinically relevant target for drug development in a rodent model of pulmonary hypertension
Elassal A, Steppan J, Charania S, Santhanam L, Singh I, Heerdt PM. Pressure-based estimation of right ventricular ejection fraction: Validation as a clinically relevant target for drug development in a rodent model of pulmonary hypertension. Journal Of Pharmacological And Toxicological Methods 2021, 112: 107102. PMID: 34245885, PMCID: PMC8616781, DOI: 10.1016/j.vascn.2021.107102.Peer-Reviewed Original ResearchConceptsRight ventricular ejection fractionPulmonary arterial hypertensionRV pressure waveformsVentricular ejection fractionEjection fractionDepressed right ventricular ejection fractionClear prognostic significanceRight ventricular pressurePressure waveformVolume measurementsPAH therapyPulmonary hypertensionArterial hypertensionPrognostic significanceBland-Altman analysisVentricular pressureRat modelRV volumesRodent modelsDrug effectsHypertensionDrug developmentBeat intervalsRatsRelevant targetsPulmonary Hypertension in Pregnancy
Singh I, Horn E, Haythe J. Pulmonary Hypertension in Pregnancy. Clinics In Chest Medicine 2021, 42: 91-99. PMID: 33541621, DOI: 10.1016/j.ccm.2020.10.006.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionPH patientsHigh maternal morbiditySystemic hemodynamic alterationsImmediate postpartum periodPotential deleterious consequencesMaternal morbidityHemodynamic alterationsPostpartum periodPhysiologic changesPregnancyCardiopulmonary circulationHypertensionPatientsDeleterious consequencesMorbidityMortality
2020
A Pressure-Based Method for Estimation of Right Ventricular Ejection Fraction in a Rodent Model of Pulmonary Arterial Hypertension
Heerdt P, Charania S, Elassal A, Singh I, Steppan J. A Pressure-Based Method for Estimation of Right Ventricular Ejection Fraction in a Rodent Model of Pulmonary Arterial Hypertension. 2020, a2086-a2086. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2086.Peer-Reviewed Original ResearchPrecision Medicine in Pulmonary Hypertension
Singh I, Oldham W, Rahaghi F. Precision Medicine in Pulmonary Hypertension. Respiratory Medicine 2020, 241-255. DOI: 10.1007/978-3-030-31507-8_16.Peer-Reviewed Original ResearchPulmonary hypertensionManagement of patientsMultiple different etiologiesPersonalized medicine approachClinical characteristicsExercise testingDifferent etiologiesInnovative biomarkersComplex pathobiologyMedicine approachHeterogeneous disorderHemodynamic analysisHypertensionPrecision medicineImaging techniquesCurrent classificationPatientsHemodynamicsEtiologyPathobiologyBiomarkers
2019
Pulmonary Vascular Distensibility and Early Pulmonary Vascular Remodelling in Pulmonary Hypertension
Singh I, Oliveira R, Naeije R, Rahaghi F, Oldham W, Systrom D, Waxman A. Pulmonary Vascular Distensibility and Early Pulmonary Vascular Remodelling in Pulmonary Hypertension. 2019, a3668-a3668. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3668.Peer-Reviewed Original ResearchMEF2 and the Right Ventricle: From Development to Disease
Clapham KR, Singh I, Capuano IS, Rajagopal S, Chun HJ. MEF2 and the Right Ventricle: From Development to Disease. Frontiers In Cardiovascular Medicine 2019, 6: 29. PMID: 30984767, PMCID: PMC6448530, DOI: 10.3389/fcvm.2019.00029.Peer-Reviewed Original ResearchPulmonary arterial hypertensionArterial hypertensionRight ventricleRight ventricular functionLife-limiting diseaseNovel therapeutic strategiesRight ventricular developmentEndothelial dysfunctionVentricular functionTherapeutic strategiesLeft ventricleHypertensionVentricleDisease statesVentricular developmentNormal physiologyMEF2 transcription factorsDiseaseAfterloadDysfunctionTranscription factors
2017
Pulmonary extra‐medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series
Singh I, Mikita G, Green D, Risquez C, Sanders A. Pulmonary extra‐medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. Pulmonary Circulation 2017, 7: 261-267. PMID: 28680586, PMCID: PMC5448544, DOI: 10.1177/2045893217702064.Peer-Reviewed Original ResearchExtra-medullary hematopoiesisPulmonary hypertensionPolycythemia veraCase seriesJanus kinase 2 mutationRecent clinical classificationKinase 2 mutationRadiological featuresRare complicationHematopoietic precursor cellsClinical classificationIdiopathic myelofibrosisEssential thrombocytosisMyeloproliferative neoplasiaMyeloid phenotypeHeterogeneous groupPrecursor cellsHypertensionGroup fiveDisordersMyelofibrosisVeraHematopoiesisPrimary expressionComplications
2015
Pathophysiology of Pulmonary Hypertension in Chronic Parenchymal Lung Disease
Singh I, Cong K, Berlin DA. Pathophysiology of Pulmonary Hypertension in Chronic Parenchymal Lung Disease. The American Journal Of Medicine 2015, 129: 366-371. PMID: 26706386, DOI: 10.1016/j.amjmed.2015.11.026.Peer-Reviewed Original ResearchConceptsLung disease-associated pulmonary hypertensionChronic obstructive pulmonary diseaseObstructive pulmonary diseasePulmonary hypertensionLung diseasePulmonary diseaseChronic parenchymal lung diseaseNormal pulmonary circulationChronic lung diseaseIdiopathic pulmonary fibrosisInterstitial lung diseaseParenchymal lung diseasePulmonary fibrosisWorse prognosisPathophysiological factorsPulmonary circulationHypertensionDiseasePathophysiologyPhysiological determinantsSarcoidosisPrognosisFibrosisExercise Intolerance in Pulmonary Hypertension
Singh I, Zappetti D. Exercise Intolerance in Pulmonary Hypertension. Clinical Pulmonary Medicine 2015, 22: 258-259. DOI: 10.1097/cpm.0000000000000122.Peer-Reviewed Original Research